Gut microbiota-derived metabolites: Potential targets for cardiorenal syndrome
Yu-Chen Lai, Yujie Zhu, Xihui Zhang, Shifang Ding, Fang Wang, Jincen Hao, Zhaomeng Wang, Congqi Shi, Yongjin Xu, Lemin Zheng, Wei Huang
Abstract
The characteristic of cardiorenal syndrome (CRS) is simultaneous damage to both the heart and kidneys. CRS has caused a heavy burden of mortality and incidence rates worldwide. The regulation of host microbiota metabolism that triggers heart and kidney damage is an emerging research field that promotes a new perspective on cardiovascular risk. We summarize current studies from bench to bedside of gut microbiota-derived metabolites to better understand CRS in the context of gut microbiota-derived metabolites. We focused on the involvement of gut microbiota-derived metabolites in the pathophysiology of CRS, including lipid and cholesterol metabolism disorders, coagulation abnormalities and platelet aggregation, oxidative stress, endothelial dysfunction, inflammation, mitochondrial damage and energy metabolism disorders, vascular calcification and renal fibrosis, as well as emerging therapeutic approaches targeting CRS metabolism in gut microbiota-derived metabolites which provides an innovative treatment approach for CRS to improve patient prognosis and overall quality of life. • Cardiorenal syndrome (CRS) is a growing global health challenge linked to changes in gut microbiota-derived metabolites. • Gut microbiota-derived metabolites are key factors in gut-heart-kidney crosstalk. • Gut microbiota-derived metabolites are closely associated with the pathogenesis of various types of CRS. • Gut microbiota-derived metabolites represent potential biomarkers for early diagnosis.